Launch is Just the Beginning: Rare Disease Care Requires Durability

Feature|Videos|July 7, 2026

Launch is Just the Beginning: Rare Disease Care Requires Durability

Author(s)Bansi Nagji, CEO, PANTHERx Rare

Key Takeaways

Understand why scientific innovation targets rare and orphan disease treatments
Learn what distinguishes a rare-only pharmacy model from traditional specialty pharmacy approaches
Recognize why launch is only the starting point for long-term therapy success

Bansi Nagji discusses the shifting science behind rare and orphan drug development, including what it takes for therapies to succeed well beyond launch

Bansi Nagji, CEO of PANTHERx Rare, explores how innovation is increasingly directed toward rare and orphan diseases, driven by targeted incentives, tax breaks, and a more streamlined FDA approval pathway. Nagji covers the operational realities that set rare disease therapies apart, including cold chain logistics, weight-based titration regimens, and the intensive patient interactions required before a single prescription is even filled. Learn why launch marks the beginning of a therapy’s journey rather than its conclusion, and why ongoing work is necessary for payer access and long-term adherence.

What's Hot

Rhythm Pharmaceuticals Receives Japan Marketing Authorization for IMCIVREE to Treat Acquired Hypothalamic Obesity

Lancaster studio makes people think differently about health and wellbeing

Scottie Scheffler reveals he played through ‘pretty painful’ illness during the BMW Championship

Launch is Just the Beginning: Rare Disease Care Requires Durability

Scottie Scheffler reveals he played through ‘pretty painful’ illness during the BMW Championship

Ex-deputy convicted of fatally shooting Sonya Massey dies in prison

Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer’s Disease Pathology in Both Primary and Specialty Care Settings

Rhythm Pharmaceuticals Receives Japan Marketing Authorization for IMCIVREE to Treat Acquired Hypothalamic Obesity

Lancaster studio makes people think differently about health and wellbeing

Scottie Scheffler reveals he played through ‘pretty painful’ illness during the BMW Championship

Clearmind Medicine Announces U.S. Publication of Patent Application for MDMA-PEA Combination in PTSD and Anxiety Treatment

Opinion: The FDA must put biotech at its center or continue to cede early research to China

Inside Elevance’s digital chronic disease management strategy

Best, Worst States For Well

What do the Middle Ages tell us about mental health then and now? VCU historian Leigh Ann Craig has answers

Fitness

Rhythm Pharmaceuticals Receives Japan Marketing Authorization for IMCIVREE to Treat Acquired Hypothalamic Obesity

Lancaster studio makes people think differently about health and wellbeing

Scottie Scheffler reveals he played through ‘pretty painful’ illness during the BMW Championship

Health

Opinion: The FDA must put biotech at its center or continue to cede early research to China

Inside Elevance’s digital chronic disease management strategy

Best, Worst States For Well

Subscribe to Updates

What's Hot

Launch is Just the Beginning: Rare Disease Care Requires Durability

Launch is Just the Beginning: Rare Disease Care Requires Durability

Key Takeaways

Related Content

Access by Design: Embedding Market Access Thinking Across the Drug Development Lifecycle

Improving Global Pharma Operations with Data

What Specialty Access Looks Like When It’s Built to Scale

An End-to-End Approach to Specialty Patient Services

What’s Next in Access & Affordability: A Biopharma Perspective

Related Posts